Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: Comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging

Journal of Magnetic Resonance Imaging

Volumn 39, Issue 5, 2014, Pages 1153-1160

  Rudolph, Andre ^a,b   Von Knobelsdorff Brenkenhoff, Florian ^a,b   Wassmuth, Ralf ^a,b   Prothmann, Marcel ^a,b   Utz, Wolfgang ^a,b   Schulz Menger, Jeanette ^a,b  

^a Medical Faculty   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

gadobenate dimeglumine; hypertrophic cardiomyopathy; late gadolinium enhancement

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE MEGLUMINE; CONTRAST MEDIUM; GADOBENIC ACID; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; FEMALE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE QUALITY; MALE; NONISCHEMIC CARDIOMYOPATHY; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; SIGNAL NOISE RATIO; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC USE; FIBROSIS; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; IMAGE ENHANCEMENT; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OBSERVER VARIATION; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; YOUNG ADULT;

EID: 84898402568     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24264     Document Type: Article

References (36)

1. Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE,. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316: 780-789.
2. Spirito P, Seidman CE, McKenna WJ, Maron BJ,. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
3. McKenna WJ, Camm AJ,. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation 1989; 80: 1489-1492.
4. Anderson KR, Sutton MG, Lie JT,. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979; 128: 79-85.
5. Emoto R, Yokota Y, Miki T, et al. [Prognosis of hypertrophic cardiomyopathy: echocardiographic and postmortem histopathologic study of 30 patients.] J Cardiol 1988; 18: 695-703.
6. Fujiwara H, Tanaka M, Onodera T, Kawai C,. [Hypertrophic cardiomyopathy: mode of death and pathological findings.] J Cardiol Suppl 1987; 16: 3-8.
7. Olivotto I, Maron MS, Autore C, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52: 559-566.
8. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43: 2260-2264.
9. Papavassiliu T, Schnabel P, Schroder M, Borggrefe M,. CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. Eur Heart J 2005; 26: 2395.
10. Maron MS,. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2009; 2: 415-425.
11. Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009; 54: 242-249.
12. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40: 2156-2164.
13. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009; 53: 284-291.
14. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56: 875-887.
15. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56: 867-874.
16. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213-221.
17. Schlosser T, Hunold P, Herborn CU, et al. Myocardial infarct: depiction with contrast-enhanced MR imaging-comparison of gadopentetate and gadobenate. Radiology 2005; 236: 1041-1046.
18. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: 2761-2796.
19. Harrigan CJ, Peters DC, Gibson CM, et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 2011; 258: 128-133.
20. Dietrich O, Raya JG, Reeder SB, Reiser MF, Schoenberg SO,. Measurement of signal-to-noise ratios in MR images: influence of multichannel coils, parallel imaging, and reconstruction filters. J Magn Reson Imaging 2007; 26: 375-385.
21. Aquaro GD, Positano V, Pingitore A, et al. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2010; 12: 21.
22. Kirchin MA, Pirovano GP, Spinazzi A,. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998; 33: 798-809.
23. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol 2006; 41: 222-228.
24. Kawel N, Nacif M, Santini F, et al. Partition coefficients for gadolinium chelates in the normal myocardium: comparison of gadopentetate dimeglumine and gadobenate dimeglumine. J Magn Reson Imaging 2012; 36: 733-737.
25. Sardanelli F, Quarenghi M,. Delayed enhancement of subendocardial infarcted myocardium with gadobenate dimeglumine: a paradoxical effect-is a double dose too much? Radiology 2006; 240: 914-915; author reply 915-916.
26. Balci NC, Inan N, Anik Y, Erturk MS, Ural D, Demirci A,. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol 2006; 13: 833-839.
27. Bauner KU, Reiser MF, Huber AM,. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol 2009; 44: 95-104.
28. Tumkosit M, Puntawangkoon C, Morgan TM, et al. Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine. J Comput Assist Tomogr 2009; 33: 328-333.
29. Laurent S, Elst LV, Muller RN,. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006; 1: 128-137.
30. Bleicher AG, Kanal E,. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR Am J Neuroradiol 2008; 29: 668-673.
31. Yrjana SK, Vaara T, Karttunen A, Koivukangas J,. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol 2008; 43: 267-275.
32. Knowles BR, Batchelor PG, Parish V, et al. Pharmacokinetic modeling of delayed gadolinium enhancement in the myocardium. Magn Reson Med 2008; 60: 1524-1530.
33. Goldfarb JW, Arnold S, Roth M,. Gadolinium pharmacokinetics of chronic myocardial infarcts: implications for late gadolinium-enhanced infarct imaging. J Magn Reson Imaging 2009; 30: 763-770.
34. Penfield JG, Reilly RF,. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 2008; 21: 129-134.
35. Heinrich M, Uder M,. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents-a status paper.] Rofo 2007; 179: 613-617.
36. Spiewak M, Malek LA, Misko J, et al. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Eur J Radiol 2010; 74: e149-153.